Neogen Corporation Deferred Revenue, Revenue Recognized
Neogen Corporation (NEOG) reported Deferred Revenue, Revenue Recognized of $11.20 million for the 12-month period ending 2026-05-31, per its 10-K filed 2026-07-30.
Financial Statements › Income Statement › Other Income
us-gaap:DeferredRevenueRevenueRecognized1 · last filed 2026-07-30
- Neogen Corporation deferred revenue, revenue recognized for the quarter ending 2026-02-28 was $2.90M, a 0.00% change year-over-year.
- Neogen Corporation deferred revenue, revenue recognized for the quarter ending 2025-11-30 was $2.63M, a 39.03% decline year-over-year.
- Neogen Corporation deferred revenue, revenue recognized for the quarter ending 2025-08-31 was $2.94M, a 41.69% increase year-over-year.
- Neogen Corporation deferred revenue, revenue recognized for the quarter ending 2025-02-28 was $2.90M, a 32.70% decline year-over-year.
- Neogen Corporation deferred revenue, revenue recognized for fiscal 2026 was $11.20M, a 4.27% decline from fiscal 2025.
- Neogen Corporation deferred revenue, revenue recognized for fiscal 2025 was $11.70M, a 11.70% decline from fiscal 2024.
- Neogen Corporation deferred revenue, revenue recognized for fiscal 2024 was $13.25M, a 11.45% increase from fiscal 2023.
- Neogen Corporation deferred revenue, revenue recognized for fiscal 2023 was $11.89M, a 45.48% increase from fiscal 2022.
| Period end | Deferred Revenue, Revenue Recognized 3 month | Deferred Revenue, Revenue Recognized 3 month as first filed | Deferred Revenue, Revenue Recognized 6 month | Deferred Revenue, Revenue Recognized 9 month | Deferred Revenue, Revenue Recognized 9 month as first filed | Deferred Revenue, Revenue Recognized 12 month | Deferred Revenue, Revenue Recognized 12 month as first filed |
|---|---|---|---|---|---|---|---|
| 2026-05-31 | $11.20M 10-K · filed 2026-07-30 | ||||||
| 2026-02-28 | $2.90M 10-Q · filed 2026-04-09 | $8.50M 10-Q · filed 2026-04-09 | |||||
| 2025-11-30 | $2.63M 10-Q · filed 2026-01-08 | $5.57M 10-Q · filed 2026-01-08 | |||||
| 2025-08-31 | $2.94M 10-Q · filed 2025-10-09 | ||||||
| 2025-05-31 | $11.70M 10-K · filed 2026-07-30 | $11.73M 10-K · filed 2025-07-30 | |||||
| 2025-02-28 | $2.90M 10-Q · filed 2026-04-09 | $2.90M 10-Q · filed 2025-04-09 | $9.20M 10-Q · filed 2026-04-09 | $9.29M 10-Q · filed 2025-04-09 | |||
| 2024-11-30 | $4.31M 10-Q · filed 2026-01-08 | $6.38M 10-Q · filed 2026-01-08 | |||||
| 2024-08-31 | $2.08M 10-Q · filed 2025-10-09 | ||||||
| 2024-05-31 | $13.25M 10-K · filed 2025-07-30 | ||||||
| 2024-02-29 | $4.31M 10-Q · filed 2025-04-09 | $4.31M 10-Q · filed 2024-04-09 | $10.22M 10-Q · filed 2025-04-09 | ||||
| 2023-11-30 | $3.23M 10-Q · filed 2025-01-15 | $5.92M 10-Q · filed 2025-01-15 | |||||
| 2023-08-31 | $2.68M 10-Q · filed 2024-10-10 | ||||||
| 2023-05-31 | $11.89M 10-K · filed 2024-07-30 | ||||||
| 2023-02-28 | $2.92M 10-Q · filed 2024-04-09 | $2.90M 10-Q · filed 2023-04-04 | $7.97M 10-Q · filed 2024-04-09 | $8.00M 10-Q · filed 2023-04-04 | |||
| 2022-11-30 | $2.86M 10-Q · filed 2024-01-09 | $5.05M 10-Q · filed 2024-01-09 | |||||
| 2022-08-31 | $2.19M 10-Q · filed 2023-10-10 | ||||||
| 2022-05-31 | $8.17M 10-K · filed 2023-08-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Celldex Therapeutics, Inc. (CLDX) | United States | $2.471B | -9.72 |
| Intellia Therapeutics, Inc. (NTLA) | United States | $1.705B | -5.92 |
| ACHIEVE LIFE SCIENCES, INC. (ACHV) | United States | $0.806B | -5.88 |
| QuidelOrtho Corp (QDEL) | United States | $0.733B | -0.90 |
| Alpha Teknova, Inc. (TKNO) | United States | $0.500B | -18.12 |
| MYRIAD GENETICS INC (MYGN) | United States | $0.397B | -4.84 |
| Insight Molecular Diagnostics Inc. (IMDX) | United States | $0.129B | -3.90 |
| IMMUCELL CORP /DE/ (ICCC) | United States | $0.091B | 116.10 |
| BIOMERICA INC (BMRA) | United States | $0.011B | |
| Q/C TECHNOLOGIES, INC. (QCLS) | United States | $0.008B | -1.93 |